Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tyra Biosciences Inc TYRA

Healthcare Biotechnology
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to... see more

Recent & Breaking News (NDAQ:TYRA)

Tyra Biosciences Inc (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire April 7, 2024

Tyra Biosciences Inc (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire April 5, 2024

Tyra Biosciences Inc (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire April 4, 2024

Tyra Biosciences Inc (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire April 3, 2024

Kaskela Law LLC Announces Investigation of Tyra Biosciences, Inc. (NASDAQ:TYRA) and Encourages Investors to Contact the Firm for Additional Information

Accesswire April 3, 2024

Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights

PR Newswire March 19, 2024

Tyra Biosciences to Present at Upcoming Investor Conferences

PR Newswire February 27, 2024

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

PR Newswire February 7, 2024

Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing

PR Newswire February 2, 2024

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia

PR Newswire February 1, 2024

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

PR Newswire December 22, 2023

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference

PR Newswire November 8, 2023

Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights

PR Newswire November 7, 2023

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

PR Newswire September 21, 2023

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference

PR Newswire September 12, 2023

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

PR Newswire August 10, 2023

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia

PR Newswire August 1, 2023

Tyra Biosciences to Participate in Upcoming Investor Conferences

PR Newswire May 25, 2023

Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights

PR Newswire May 4, 2023

Tyra Biosciences to Participate in Upcoming Investor Conferences

PR Newswire March 29, 2023